Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05982340
  4. Details
NCT05982340 Clinical Trial

Endogenous Lithium Clearance in Acute Kidney Injury

Acute Kidney Injury Due to Sepsis Clinical Trial

Official title:
Endogenous Lithium Clearance in Acute Kidney Injury

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05982340
Other study ID # 03055 PVO
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2023
Est. completion date December 31, 2024

Study information
Verified date July 2023
Source University Hospital of North Norway
Contact Lars Marius Ytrebø
Phone 90788058
Email lars.marius.ytrebo@unn.no
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Critically ill patients are at high risk of developing acute kidney injury (AKI). Lithium is freely filtrated at the glomerulus and almost completely reabsorbed in the proximal tubule, which provides a quantitative estimation of proximal tubule reabsorption. The investigators hypothesized that endogenous lithium reabsorption is impaired in the early stages of critical illness. Investigators would like to study 10 ICU patients with AKI diagnosed, 10 patients without AKI, and 10 healthy controls.

Description:

Blood and urine samples will be obtained at 08:00, 14:00 and 20:00 during one day. Renal clearance of creatinine (CCr) and lithium will be calculated.

Recruitment information / eligibility
Status Recruiting
Enrollment 30
Est. completion date December 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ICU patients diagnosed with AKI, without AKI and healthy controls Exclusion Criteria: -

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Lithium clearance
Blood and urine samples

Locations
Country Name City State
Norway University Hospital of North Norway Tromsø Troms

Sponsors (1)
Lead Sponsor Collaborator
University Hospital of North Norway

Country where clinical trial is conducted

Norway, 

Outcome
Type Measure Description Time frame Safety issue
Primary Renal lithium clearance Clearance of lithium from the body 2 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05114057 - Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI N/A
Completed NCT05507437 - Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury Phase 2
Terminated NCT04411472 - (Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI Phase 3
Recruiting NCT05939245 - Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group N/A
Recruiting NCT06295393 - Renin Angiotensin Aldosterone System In Septic Kids
Completed NCT04633746 - Plasma Endostatin Predicts Outcome of Septic AKI
Recruiting NCT05996835 - Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI) Phase 2
Recruiting NCT05575024 - Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane
Completed NCT05060679 - Presepsin:Gelsolin Ratio in Sepsis-related Organ Dysfunction
Completed NCT04968262 - Urinary Actin, as a Potential Marker of Sepsis-related Acute Kidney Injury
Not yet recruiting NCT05559086 - N/LP Ratio as Predictor of Mortality in Septic AKI Patients